One shot or two? study tests combo Weight-Loss injection
NCT ID NCT04940078
First seen Nov 01, 2025 · Last updated Jun 18, 2026 · Updated 39 times
Summary
This study looked at two weight-loss medicines, cagrilintide and semaglutide, given to 40 adults with overweight or obesity. For 14 weeks, everyone got separate shots. Then, for 8 weeks, some got a combined single shot while others kept separate shots. The goal was to measure medicine levels in the blood, not to test weight loss. The study lasted about 8 months with many clinic visits and blood draws.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY & OVERWEIGHT are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Altasciences Company Inc.
Montreal, Quebec, H3P 3P1, Canada
-
Novo Nordisk Investigational Site
Søborg, 2860, Denmark
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.